Next Phase Newsletter

The corporate venture capital arm of a large pharmaceutical company is currently looking to make equity investments into early stage life science companies. The firm has the ability to allocate up to $10 million dollars per company, generally in milestone driven tranches. The firm is able to invest in companies from around the globe and is actively seeking new investment opportunities.

The firm is looking for early stage companies working with therapeutics and companion diagnostics. The firm is open to review both small molecules and biologics as well as companies working with single assets or platform technologies. The firm seeks to invest in indication areas including Immunology, Oncology, Immunoncology, MS, and Fertility. The firm generally looks for companies with assets that are pre-clinical or in Phase I of clinical trials.

The firm is looking for privately held companies with experienced management teams. The firm looks to take an active role following investing generally taking at least a board seat. The firm is willing to both lead rounds and co-invest as a member of a syndicate.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

The corporate venture capital firm that is funded by two substantial healthcare providers makes private equity investments of strategic interest to the systems medical centers and affiliated physicians. The firm makes investment ranging anywhere from $1-$8 million over the life of the investment with the majority of allocations falling in the $5-$7 million range. The firm manages an evergreen structure and is actively looking for new opportunities throughout the United States.

The firm is currently interested in healthcare information technology, tech-enabled medical devices and tech-enabled healthcare services. For medical devices the firm is focused on tech enabled devices and is highly interested in areas of patient monitoring and wearables, among other areas. The firm is also interested in highly innovative hospital hardware and devices that have the potential to significantly lower the cost of the point of care process. The firm generally invests in companies in the series A and B rounds.

The firm is looking for companies with experienced management teams. The firm looks to act as a strategic investor generally taking a board seat. The firm is very open to syndication and general invests along with other institutional investors.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

An angel network based out of the North Eastern United States looks to make equity investments in early-stage and selectively seed stage life science companies ranging from $.5 – $1.5 million. The firm is also open to syndication on larger deals and will consider opportunities throughout the United States and Canada. The firm plans to allocate to 10 new companies over the next year. The group is open to sectors in the life science space including therapeutics, diagnostics and medical devices. The firm is generally opportunistic in terms of technology type, indication and is open to both small molecules and biologics. The firm is comfortable in investing in series A, B, C, or D rounds and is willing to invest in technologies that are pre-clinical or in early clinical trials. The group is most interested in investing in companies with experienced management teams though they also consider spinouts from universities in certain situations. The firm looks to invest in privately held companies and generally takes a seat on the company’s board. If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A venture capital firm based in China makes early-growth stage investments in the life science sector, preferably in series A and B; the firm may also consider series C opportunities. The firm typically invests RMB 100 million (USD 16 million) or more per company. The firm prefers to invest in companies based in China, but is open to outstanding opportunities from around the globe. The firm is actively seeking new investment opportunities.

In the life sciences, the firm is most interested in mHealth, gene sequencing, immunotherapy, stem cells, and antibody therapeutics. The firm is indication agnostic. The firm is also opportunistic to other cutting edge technologies in the healthcare industry. The firm is open to investing in companies in the pre-clinical phase of development as well as those that have clinical data.

The firm seeks a strong and experienced management team and generally looks to take a board seat following investment.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A private/family investment vehicle based in the Western United States is seeking to invest in the life science space.  The fund is a structured organization for making angel investments in pre-seed or seed rounds.  Investments are in the form of equity; in the next 6 months the firm expects to make about 5-10 seed investments of $50,000-100,000 and an additional 40 pre-seed investments of $25,000, and is hoping to increase their allocations in the healthcare sector.  The firm also provides a three-month accelerator program.  The firm will consider investing in companies worldwide.

The firm is interested in investing in medical technology, and invests in subsectors in which the firm can apply expertise; typically this means products that have a significant software component.  Healthcare IT, biosensors, wearables and health monitoring devices are of interest.  While the firm is open to investing in any indication, the firm is particularly interested in diabetes & blood glucose monitoring, personal fitness, and mental/behavioral disorders.  In the healthcare IT sector, the firm is interested in both consumer applications and enterprise software, but is not interested in diagnostic software such as genomic, proteomic or molecular diagnostic algorithms; however, optimization and data analysis software for hospitals and diagnostic laboratories is of interest.

The firm prefers to invest in companies with at least two co-founders, one with technical expertise and one with business expertise; for the accelerator program in particular, the firm prefers to work with companies that have a technical expert co-founder.  In addition to due diligence on the management team and technology, the firm also considers a product’s potential market opportunity.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

Allocation Information

The corporate venture capital arm of a global pharmaceutical company based in Mumbai, India is actively seeking new investments. The firm has been established to invest in early stage ideas with breakthrough technologies addressing major unmet medical needs. The firm seeks to make equity investments in Seed and Series A/B rounds. The firm has a global mandate and is currently seeking new investment opportunities.

Sectors and Subsectors of Interest

The firm is currently seeking to invest in early to mid-stage repurposed drugs, repositioned drugs, combination therapies, and new delivery technologies and devices for old drugs. In terms of indications, the firm is focused on oncology, neurology, infectious diseases, and metabolic diseases, but will consider other indications on a case-by-case basis. The firm will prioritize 505(b)(2) opportunities.

Company and Management Team Requirements

The firm seeks companies with a strong and experienced management team. The firm may take a board seat/board observer rights.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A global private equity firm is looking to make direct equity investments into life science companies ranging from $5-25m, primarily in the USA and Europe, with the potential to invest in other areas if the right syndication opportunities are available.  The firm typically makes 10 new direct investments per year across a diverse range of sectors, including healthcare IT, therapeutics and medical devices.  The firm leads or co-leads financing rounds in about 60% of cases and takes a board seat in these instances, but on other occasions may syndicate with other investors and not take a board seat.

The firm prefers to invest in medical devices and therapeutics with the potential to become the standard of care in a large clinical area with unmet needs.  Focus indications include oncology, immunology, cardiology, diabetes, neurology, infectious diseases, respiratory disorders, pain management and psychiatry.  The firm prefers to invest in the later clinical stages (Phase II + III), but will consider opportunistic investments in earlier stage opportunities if the firm sees the potential for outsized risk-adjusted returns due to a market dislocation.

The firm also invests in healthcare IT companies that have a product already on the market and have attained revenue and customer adoption.  These investments are in a variety of market segments, including enterprise software, clinical management software, connected devices/equipment and direct-to-consumer products.

In the therapeutic and medical device sectors, the firm seeks to invest in companies with unique intellectual property and with strong investor syndicates who can fund late-stage clinical trials to completion.  In the healthcare IT sector, the firm prefers to invest in companies with at least $5m in revenue and strong, experienced management teams.  The firm performs thorough due diligence, looking at factors such as historical performance, size of market opportunity, revenue per customer and customer stickiness in addition to vetting the product itself and the management team.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com